Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMGEN OBESITY GENE WEIGHS IN FAVORABLY IN JULY, STOCK GAINS 4-3/4 POINTS; BIOTECH BOOMS IN MONTH, WITH "F-D-C" INDEX PHARMACEUTICAL COMPONENT GAINING 9.5%

Executive Summary

The enthusiastic reception by investors of Amgen's preclinical work on the obesity gene is evidence that the luster is back on biotechnology

You may also be interested in...



Repurposing Leptin: How a “Fat Drug” Became a Model for a Leaner Industry

Two decades ago, the “fat dissolving” protein leptin was touted as one of the biggest opportunities in biotech—based on preclinical rodent studies. The compound may finally be making it to market in a very different model: as an orphan drug sponsored by Big Pharma.

Amgen Paying $1.3 Bil. For Tularik; Deal Brings Two Late-Stage Oncologics

Amgen is acquiring two late-stage oncology compounds through its $1.3 bil. buyout of Tularik

Amgen Paying $1.3 Bil. For Tularik; Deal Brings Two Late-Stage Oncologics

Amgen is acquiring two late-stage oncology compounds through its $1.3 bil. buyout of Tularik

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel